DNAprint Genomics (DNAG)

[worktoplay]

I get the picture...what you're saying is that you can't figure out how DNAPrint management turned a $2 million dollar investment into $5.9 million in less than two years, and then managed to get cash out of the restricted Biofrontera shares so as to help fund current operations, AND maintain an option to repurchase depending on what happens to the value of those Biofrontera shares between now and October...is that what you mean?

BTW, you DO understand that should Biofrontera's trials go well, and the shares appreciate above $16.13 euro per share, DNAPrint would likely seek a way to reacquire the shares.

Later,
W2P